Veracyte, Inc. (VCYT)
NASDAQ: VCYT · Real-Time Price · USD
30.68
+1.91 (6.64%)
At close: Aug 13, 2025, 4:00 PM
30.01
-0.67 (-2.18%)
Pre-market: Aug 14, 2025, 8:49 AM EDT
Veracyte Revenue
Veracyte had revenue of $130.16M in the quarter ending June 30, 2025, with 13.75% growth. This brings the company's revenue in the last twelve months to $479.13M, up 19.91% year-over-year. In the year 2024, Veracyte had annual revenue of $445.76M with 23.46% growth.
Revenue (ttm)
$479.13M
Revenue Growth
+19.91%
P/S Ratio
4.98
Revenue / Employee
$581,467
Employees
824
Market Cap
2.41B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 445.76M | 84.71M | 23.46% |
| Dec 31, 2023 | 361.05M | 64.52M | 21.76% |
| Dec 31, 2022 | 296.54M | 77.02M | 35.09% |
| Dec 31, 2021 | 219.51M | 102.03M | 86.85% |
| Dec 31, 2020 | 117.48M | -2.89M | -2.40% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
VCYT News
- 7 days ago - Veracyte, Inc. (VCYT) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Veracyte Announces Second Quarter 2025 Financial Results - Business Wire
- 27 days ago - Veracyte to Release Second Quarter 2025 Financial Results on August 6, 2025 - Business Wire
- 5 weeks ago - Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025 - Business Wire
- 2 months ago - Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research - Business Wire
- 3 months ago - Veracyte to Participate in Upcoming Investor Conferences - Business Wire
- 3 months ago - Veracyte, Inc. (VCYT) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Veracyte Announces First Quarter 2025 Financial Results - Business Wire